Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

unique mechanism of action as a non-chain terminating nucleoside analog HBV polymerase inhibitor may demonstrate additive antiviral benefit in combination with tenofovir's recently demonstrated antiviral potency in HBV," stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "We also plan to reproduce the results from earlier studies demonstrating clevudine's ability to provide a sustained virologic response in patients with eAg negative chronic HBV infection, as either monotherapy or in combination, offering infected individuals and their physicians an important new treatment option."

Ongoing Registration Studies for New Drug Application (NDA)

The ongoing clevudine Phase 3 registration program includes two 48-week clinical trials designed to demonstrate the superiority of clevudine 30mg over Hepsera(R) (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. Pharmasset plans to submit the 48-week data from these studies to the FDA as the basis for the clevudine marketing approval. Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information about the clevudine registration studies.

South Korean Registration Studies for Clevudine

Bukwang received marketing approval for clevudine from the South Korean FDA based on two 24-week, placebo-controlled, double-blind, randomized, multi-center South Korean Phase 3 registration trials in 337 patients. Study 301 enrolled 248 HBeAg+ patients who received clevudine 30 mg or a placebo once-daily, and Study 302 enrolled 89 HBeAg- patients who received clevudine 30 mg or a placebo once-daily. All patients were evaluated for an additional 24 weeks of follow-up care without clevudine treatment.

At 24 weeks on treatment with clevudine, 59% of HBeAg+ patients achieved undetectable HBV DNA and 92% of HBeAg- patients achieved undetec
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Thousands of people will peacefully demonstrate their frustration ... epidemic at dozens of rallies across the country today. ... the United States has experienced skyrocketing rates ... heroin, yet the President has never once spoken publicly ... to President Obama , rally organizers compared his failure ...
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival ... Tuesday, September 1. , “Alive Inside” shadows a social worker who advocates for the ... “It’s a documentary about bringing music to residents in health care centers who may ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... formed in 2008, the result of a merger of five of the busiest ... cooperatively, they could provide more cost-effective and higher quality care than they did ...
(Date:8/31/2015)... ... 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been ... Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. ... in both sports in his senior year. He was inducted into the National Honor ...
(Date:8/31/2015)... ... ... Dr. Stewart Shofner of Shofner Vision Center explains what causes ... comprehensive eye examination can diagnose amblyopia. According to the National Eye Institute ... 2 to 3 out of every 100 children. , Dr. Shofner adds, “unless ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
Breaking Medicine News(10 mins):Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
... the first device able to transmit American Sign Language ... its initial field test by participants in a UW ... the first study of how deaf people in the ... Eve Riskin, a UW professor of electrical engineering. The ...
... MONDAY, Aug. 16 (HealthDay News) -- Folks with Internet connections ... folks without access to the Web, a new study shows. ... the old standby, "friends," as the number one way to ... at the American Sociological Association annual meeting in Atlanta. ...
... , HOUSTON - A protein associated with cancer progression ... creation of new blood vessels that feed the tumor ... University of Texas MD Anderson Cancer Center reports in ... using a nanoparticle-based gene-silencing system to block production of ...
... (Aug. 16, 2010) -- Researchers at Rice University have won ... determine whether a disease outbreak is caused by a natural ... terrorists. The three-year grant -- Rice,s first from the ... security and public health officials with the tools they need ...
... from Mount Sinai School of Medicine have for the ... plaques vulnerable to rupture using multi-color computed tomography (CT), ... diagnosis of cardiovascular disease. The data are published in ... of atherosclerotic plaques are the cause of nearly 70 ...
... DETROIT The Donor Risk Index, which assesses donor characteristics ... on outcomes on a small scale as is suggested from ... to continue to be the major contributor to poor graft ... The goals of the study were to confirm ...
Cached Medicine News:Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3Health News:Web Connection Raises Chances of Romance 2Health News:Web Connection Raises Chances of Romance 3Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 2Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 3Health News:Telltale signs of bioterror 2Health News:Mount Sinai pioneers new cardiac imaging device 2Health News:Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale 2
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
... New REFRESH LIQUIGEL® Lubricant Eye Drops ... with the convenience of a liquid ... protection. Its extra-strength CMC formula provides ... comfort. And with the PURITE® preservative, ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
... solution is an anti-infective prescription ... may instruct you to use ... infection caused by bacteria. Bacterial ... the 2 types of eye ...
Medicine Products: